Modus Therapeutics secures access to bridge financing from Karolinska Development
STOCKHOLM, SWEDEN - 12 May 2022: Modus Therapeutics Holding AB (“Modus”) announces that it has secured access to bridge financing of up to SEK 11.5 million from its largest shareholder, Karolinska Development. Access to this potential funding will ensure that momentum of clinical development of the company’s lead asset, sevuparin, for the treatment of sepsis is sustained. This includes the planning for the forthcoming Phase 2a study in patients with sepsis that is expected to begin before the end of 2022.John Öhd, CEO of Modus Therapeutics, said: “We are pleased to have secured access to